2023-05-03 16:46:36 ET
- Vanda Pharmaceuticals press release ( NASDAQ: VNDA ): Q1 GAAP EPS of $0.06.
- Revenue of $62.5M (+3.8% Y/Y).
- Given uncertainties surrounding the U.S. market for HETLIOZ for the treatment of Non-24 as a result of the ongoing HETLIOZ patent litigation and the at-risk launch of a generic version of HETLIOZ, VNDA is unable to provide 2023 financial guidance at this time.
- HETLIOZ net product sales will likely decline in future periods, potentially significantly, related to the at-risk launch of a generic version of HETLIOZ in the U.S.
For further details see:
Vanda Pharmaceuticals reports Q1 results